CD62L测试的2年natalizumab预测渐进多焦点的脑白质病

脚注

• Coinvestigators列出在半岛投注体育官网Neurology.org。

• 补充数据半岛投注体育官网Neurology.org

• 作者的贡献:安塞:数据采集,进行实验,数据分析和解释,写的手稿。n。,T.S.-H., M.C., C.L.-F., H.W.: data interpretation, revised the manuscript. F.B.: data collection, performed the experiments. D.B., D.A.-P., O.O., J.-C. Ongagna, J.d.S., B.B., J.-C. Ouallet, M.D., S.P., G.D., N.D., P.H., A.T., P.L., G.C., E.B., J.P., A.R., H.Z., D.L., S.W., W.C., E.T., O.C., T.M., A.F., S.V., C.P., P.V., C.L.-F.: sample and data collection, revised the manuscript. D.B.: study design, data analysis and interpretation, wrote the manuscript.

• 研究经费:本研究获得资金从法国卫生部(PHRC 2008-005906-38), ARSEP女士(法国社会资助2009年和2011年),和欧盟(BEST-MS FP7,之下305477 - 2012)。安塞是由一个ARSEP格兰特(2016)。

• 披露:b Pignolet报告没有披露相关的手稿。从生原体n . Schwab收到旅行资金,从诺华议长谢礼,持有专利的使用L-selectin作为PML的预测标志。t . Schneider-Hohendorf收到生原体和旅行的资金持有专利的使用L-selectin作为风险的预测标记开发PML。f . Bucciarelli d Biotti, d . Averseng-Peaureaux报告没有披露相关的手稿。o . Outtteryck Teva制药公司的个人费用和非金融支持报告;拨款,个人费用,从生原体和非金融支持;赠款和非金融支持诺华;从Bayer-Pharma非金融支持;个人费用和非金融Genzyme的支持;外从Merck-Serono和非金融支持,提交工作。 J.-C. Ongagna, J. de Seze, B. Brochet, J.-C. Ouallet, M. Debouverie, and S. Pittion report no disclosures relevant to the manuscript. G. Defer reports personal fees from Biogen Idec, Novartis, Sanofi Aventis, Genzyme, and Teva Pharmaceutical Industries Ltd.; other from Merck Serono, Biogen Idec, Guerbet, Sanofi-Aventis, Novartis, Genzyme, and Teva Pharmaceutical Industries Ltd.; and grants from Novartis, Merck Serono, and Teva, outside the submitted work. N. Derache reports personal fees from Biogen-Idec, Genzyme, Novartis, Teva, and Merck-Serono, outside the submitted work. P. Hautecoeur reports no disclosures relevant to the manuscript. A. Tourbah has received in the last year, consulting and lecturing fees, travel grants and research support from Medday, Biogen Idec, Sanofi-Genzyme, Novartis, Merck Serono, Teva Pharma, and Roche. P. Labauge, P. Clavelou, and E. Berger report personal fees from Biogen Idec, personal fees from Genzyme-Sanofi, personal fees from Teva, and personal fees from Novartis, outside the submitted work. J. Pelletier and A. Rico report no disclosures relevant to the manuscript. H. Zéphir reports grants from ARSEP; personal fees and nonfinancial support from Biogen Idec; personal fees and nonfinancial support from Bayer; personal fees and nonfinancial support from Genzyme-Sanofi; grants, personal fees, and nonfinancial support from Teva; personal fees and nonfinancial support from Novartis; and nonfinancial support from Merck, outside the submitted work. D. Laplaud reports personal fees from Biogen, personal fees from Teva Pharma, grants and personal fees from Novartis Pharma, grants and personal fees from Genzyme, and personal fees from Merck-Serono, outside the submitted work. S. Wiertlewski reports personal fees from Novartis, personal fees from Genzyme, personal fees from Biogen Idec, and personal fees from Teva, outside the submitted work. W. Camu and E. Thouvenot report no disclosures relevant to the manuscript. O. Casez reports grants, personal fees, and nonfinancial support from Biogen; grants, personal fees, and nonfinancial support from Novartis; grants, personal fees, and nonfinancial support from Genzyme; grants from Merck; grants and personal fees from Teva; and grants from Bayer Schering, outside the submitted work. T. Moreau reports personal fees and nonfinancial support from Biogen, personal fees and nonfinancial support from Novartis, personal fees and nonfinancial support from Sanofi Genzyme, personal fees and nonfinancial support from Bayer, personal fees and nonfinancial support from Merck, personal fees and nonfinancial support from Teva, personal fees and nonfinancial support from Almirall, and personal fees and nonfinancial support from Roche, outside the submitted work. A. Fromont, S. Vukusic, and C. Papeix report no disclosures relevant to the manuscript. P. Vermersch reports grants, personal fees, and nonfinancial support from Biogen; grants, personal fees, and nonfinancial support from Bayer; personal fees and nonfinancial support from Novartis; grants, personal fees, and nonfinancial support from Genzyme-Sanofi; personal fees and nonfinancial support from Almirall; and personal fees and nonfinancial support from Teva, outside the submitted work. M. Comabella reports personal fees from Bayer Schering Pharma, personal fees from Merck Serono, personal fees from Biogen-Idec, personal fees from Teva Pharmaceuticals, personal fees from Sanofi-Aventis, personal fees from Genzyme, and personal fees from Novartis, outside the submitted work. C. Lebrun-Frenay reports no disclosures relevant to the manuscript. H. Wiendl is on the scientific advisory board for Bayer Healthcare, Biogen Idec, Sanofi-Genzyme, Merck Serono, Novartis, Roche, and Teva; received travel funding and/or speaker honoraria from Bayer Vital GmbH, Bayer Schering AG, Biogen, CSL Behring, EMD Serono, Fresenius Medical Care, Sanofi-Genzyme, Merck Serono, OmniaMed, Novartis, and Teva; is on the editorial board for《临床实践,《神经炎症,《公共科学图书馆•综合》;咨询了Idec,默克公司Serono,诺华,OmniaMed,罗氏,Sanofi-Genzyme;收到拜耳医药保健有限公司的研究支持,拜耳至关重要,Idec,默克公司Serono,诺华,Sanofi-Genzyme,赛诺菲安万特美国,和梯瓦制药公司。d Brassat报告个人费用从拜耳先灵葆雅制药、Idec, EMD默克公司Serono, Genzyme,诺华,赛诺菲-安万特(sanofi - aventis)和梯瓦制药。去半岛投注体育官网Neurology.org完全披露